The European Medicines Agency (EMA) and the European Commission have been providing guidance to help pharmaceutical companies prepare for the consequences of Brexit since 2017. This includes companies responsible for human medicines and for veterinary medicines, both centrally and nationally authorised.

On 20 November 2017, European Union (EU) Member States decided to relocate the European Medicines Agency (EMA) to Amsterdam, the Netherlands, as a result of the United Kingdom's (UK) withdrawal from the EU. The Agency immediately began working with the Dutch authorities to prepare for the move and take up its operations in Amsterdam by 30 March...